Latest Headlines

Latest Headlines

Pfizer hits bump on Prevnar 13 growth curve

Pfizer catapulted itself into the vaccine big leagues in 2009 by merging with Wyeth, and continued demand for Prevnar 13 has seen it consolidate its position. Analysts predict its sales could dwarf other vaccines--hitting $6.7 billion in 2018--but recent quarters suggest it will be a bumpy ride.

Novartis lands EU approval of meningitis B vaccine Bexsero

Novartis nabbed EU approval of Bexsero, a meningitis B vaccine the company has been banking on to bolster its lagging vaccine unit.

Novartis nabs EU approval for meningitis B vaccine Bexsero

Novartis has won European approval of Bexsero, its new meningitis B vaccine, which is central to the Big Pharma's drive to grow its big vaccine unit.

Novartis rides high on Bexsero study results

Novartis, still riding high on a European Medicine Agency committee backing of its meningitis vaccine Bexsero, confirmed more upbeat results from a study showing the shot offered broad protection to infants.

Novartis nabs EU committee backing for meningitis B vaccine

Novartis ($NVS) hit a key turning point with its vaccines division when a European Union committee backed the company's Bexsero meningitis shot.

Novartis vaccines unit's future hangs on Bexsero approval

Novartis' ($NVS) vaccine business is hanging in the balance, relying on the potential approval of a shot to protect against a meningitis-causing bacteria to keep the unit afloat.

Novartis vaccine Bexsero combats meningitis

Novartis ($NVS) is reporting its vaccine Bexsero stimulated an immune response against three strains of the meningococcus B bacterium. An approval would open the door to jabs that would combat the

Novartis' Bexsero successfully protects vast majority of infants

A vaccine against meningococcal B disease, a devastating bacterial infection that is hard to diagnose and can kill in 24 hours, has come a step closer with infant Phase IIb data for Novartis' ($NVS)

Novartis vax against MenB shows benefits in infant study

Novartis appears to have made more progress in the battle against meningitis B. The Swiss drug giant says that its experimental vaccine Bexsero (a.k.a. 4CMenB) could protect against about 80 percent